COLL
Collegium Pharmaceutical, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
16.32
PEG
—
P/B
3.40
P/S
1.31
EV/EBITDA
2.86
DCF Value
$758.91
FCF Yield
31.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
59.3%
Operating Margin
23.0%
Net Margin
8.1%
ROE
24.1%
ROA
7.5%
ROIC
9.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $205.4M | $17.0M | $0.46 |
| FY 2025 | $780.6M | $62.9M | $1.73 |
| Q3 2025 | $209.4M | $31.5M | $0.84 |
| Q2 2025 | $188.0M | $12.0M | $0.34 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.77
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.